関連する実験動画
Updated: Feb 20, 2026

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.4K
OPTNノックアウトは,マウスモデルにおける喘息のOVA誘発性呼吸道炎症を緩和する
Yujing Zhang1, Zixian Wang1, Jing Chen1
1Xuzhou Medical University, Xuzhou City, China.
Molecular immunology
|February 18, 2026
まとめ
オプティヌーリン (OPTN) 遺伝子ノックアウトは,マウスモデルにおける喘息の呼吸道炎症とアレルギー反応を著しく減少させます. これは,OPTNがオートファギーの調節に役割を果たし,潜在的に喘息の新たな治療標的を提供することを示唆しています.
科学分野:
- 免疫学 免疫学とは
- 呼吸器医学とは
- 分子生物学は分子生物学である.
背景:
- 喘息は慢性炎症性呼吸器疾患の1つである.
- オプティヌーリン (OPTN) は,様々な細胞プロセスに関与するタンパク質です.
- 喘息の病原性におけるOPTNの役割は,ほとんど未知のままである.
研究 の 目的:
- オバルブミン (OVA) 誘発性喘息マウスモデルにおける呼吸道炎症に対するオプティヌーリン (OPTN) 遺伝子ノックアウトの影響を調査する.
- オートファギーの調節を含む,喘息におけるOPTNの役割の潜在的メカニズムを探求する.
主な方法:
- ワイルドタイプとOPTNノックアウトマウスにおけるオバルブミン (OVA) 感受性を用いて慢性喘息モデルを確立しました.
- H&EとPAS染色による肺炎とゴブレット細胞増殖の評価.
- ELISAを用いた定量化された炎症媒介体 (IL-33,TSLP,IL-25,IL-4,IL-5,IL-13,IGE) について.
- 免疫ヒストケミストリーとウェスタン・ブラッティングによる自己死性のマーカー (LC3,p62) を評価し,クロロクイン投与と投与なしで評価した.
主要な成果:
- OPTN欠乏症は,OVA誘発の呼吸道炎症を著しく軽減し,炎症性細胞の浸透,基礎膜の厚み,粘液の産生を減少させました.
- ブロンコアルベオラ洗浄液中の血清IgEレベルとキーアラミンとTh2サイトカインの濃度は,OPTNノックアウトマウスで著しく低下しました.
- オートファギーのマーカーであるLC3とp62の変異表現はOPTN欠乏した肺に観察され,オートファギーの調節における役割を示唆したが,クロロクイン治療群では統計的有意性は得られなかった.
結論:
- オプティヌーリン (OPTN) ノックアウトは,マウスモデルにおける喘息のような呼吸道炎症を効果的に軽減します.
- 根本的なメカニズムは,OPTNによるオートファギーの調節を含む可能性があります.
- OPTNをターゲットにすることは,喘息の管理のための新しい治療戦略を表す可能性があります.
関連する概念動画
Asthma: Pathogenesis and Management
1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K

